BI drug gets priority review

Share this article:

The FDA bestowed priority review status on Boehringer Ingelheim's experimental idiopathic pulmonary fibrosis treatment nintedanib. The treatment also has orphan drug status—the progressive and fatal lung disease is a rare condition which affects around 132,000 patients in the US.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.